Glioblastoma Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals

DelveInsight's analysis of the Glioblastoma pipeline reveals over 200 key companies working on 220+ treatment therapies

Published on Feb. 12, 2026

Got story updates? Submit your updates here. ›

According to DelveInsight's assessment, the global Glioblastoma pipeline consists of 200+ key companies continuously working towards developing 220+ Glioblastoma treatment therapies. The report provides a comprehensive analysis of the clinical trials, therapies, mechanism of action, route of administration, and developments in the Glioblastoma market.

Why it matters

Glioblastoma is the most aggressive and common form of primary brain cancer in adults, with a high unmet need for effective treatments. The Glioblastoma pipeline report highlights the significant research and development efforts by various companies to address this critical medical challenge.

The details

The Glioblastoma Pipeline Insight report by DelveInsight provides a detailed analysis of the current clinical development scenario and growth prospects across the Glioblastoma market. The report covers in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase, including the mechanism of action, clinical studies, regulatory approvals, and product development activities.

  • In January 2026, ImmunityBio, Inc. announced updated Phase 2 data from its QUILT 3.078 trial assessing a chemotherapy-free combination immunotherapy approach in patients with second-line recurrent or progressive glioblastoma.
  • In November 2025, GenomOncology announced a strategic collaboration with the Glioblastoma Foundation to advance genomic testing for glioblastoma.
  • In June 2025, Diakonos Oncology secured $20 million to accelerate its Phase II glioblastoma trial of dubodencel and expand its clinical portfolio.
  • In May 2025, the Phase 2b SURVIVE study evaluating SurVaxM, a cancer vaccine, in patients with newly diagnosed glioblastoma will proceed based on interim trial data analysis.
  • In November 2024, Shuttle Pharma expanded its Phase II trial of ropidoxuridine for glioblastoma, with the first patient cohort now receiving treatment.

The players

Denovo BioPharma

A biopharmaceutical company developing novel therapies for cancer, including the Glioblastoma drug Enzastaurin.

Apogenix

A biopharmaceutical company developing the Glioblastoma drug Asunercept.

Cantex

A pharmaceutical company developing the Glioblastoma drug Azeliragon.

ImmunityBio, Inc.

A commercial-stage immunotherapy company focused on cytokine-based and cellular immunotherapies for Glioblastoma.

GenomOncology

A biotechnology company collaborating with the Glioblastoma Foundation to advance genomic testing for Glioblastoma.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The Glioblastoma pipeline report highlights the significant research and development efforts by various companies to address the critical medical challenge of this aggressive brain cancer. With over 200 key companies working on 220+ treatment therapies, the Glioblastoma market is poised for advancements in the coming years, offering hope for improved outcomes for patients.